Lataa...
Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly potent integrase inhibitor, with a half-life of up to 54 days, allowing for every other month parenteral administrations...
Tallennettuna:
| Julkaisussa: | Biomaterials |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5926202/ https://ncbi.nlm.nih.gov/pubmed/29059541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biomaterials.2017.10.023 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|